American Association for Cancer Research
Browse

Table TS1 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy

Download (14.36 kB)
journal contribution
posted on 2023-04-04, 01:43 authored by Carmen A. Widmer, Ismar Klebic, Natalya Domanitskaya, Morgane Decollogny, Denise Howald, Myriam Siffert, Paul Essers, Zuzanna Nowicka, Nadine Stokar-Regenscheit, Marieke van de Ven, Renske de Korte-Grimmerink, José A. Galván, Colin E.J. Pritchard, Ivo J. Huijbers, Wojciech Fendler, Conchita Vens, Sven Rottenberg

gRNA oligos used for the generation of Lrrc8a or Lrrc8d-knockout cell lines, organoids and tumors

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)

EC | ERC | HORIZON EUROPE European Research Council (ERC)

Krebsliga Schweiz (Swiss Cancer League)

Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)

History

ARTICLE ABSTRACT

We demonstrate that lack of expression of Lrrc8a or Lrrc8d significantly reduces the uptake and efficacy of cisplatin and carboplatin in Pt-sensitive BRCA1;p53-deficient tumors. Moreover, our work provides support to confirm the LRRC8A and LRRC8D gene expression in individual tumors prior to initiation of intensive Pt-based chemotherapy.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    BiomarkersBreast CancerDrug ResistanceHead, Neck & Oral CancersChemotherapyPrecision Medicine

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC